Recommendations on Second-line Chemotherapeutic Options for Advanced Non-Small Cell Lung Cancer (NSCLC)

It is recommended for the patient to consider participation in clinical trials.

Non-squamous NSCLC refers to the non-flat shape of cancer cells determined from examinations such as a biopsy, where a sample of the tumour is removed for analysis. This allows doctors to categorize types of cancer. Docetaxel or pemetrexed (for non-squamous cancer) can be used in fit patients as second-line treatment of advanced lung cancer. Docetaxel is an anti-cancer drug that inhibits cancer cell division. Pemetrexed is a drug that inhibits production of DNA and RNA and hence prevents cell growth, specifically of cancer cells since they actively produce DNA and RNA.